| Market Cap | 4.59M | P/E | - | EPS this Y | 25.40% | Ern Qtrly Grth | - |
| Income | -110.42M | Forward P/E | -0.08 | EPS next Y | 31.80% | 50D Avg Chg | -94.00% |
| Sales | 105.86M | PEG | -0.01 | EPS past 5Y | - | 200D Avg Chg | -99.00% |
| Dividend | N/A | Price/Book | 0.08 | EPS next 5Y | 10.00% | 52W High Chg | -99.00% |
| Recommedations | 3.00 | Quick Ratio | 0.77 | Shares Outstanding | 183.40M | 52W Low Chg | 44.00% |
| Insider Own | 17.36% | ROA | -25.29% | Shares Float | 112.30M | Beta | 0.70 |
| Inst Own | 74.60% | ROE | -108.91% | Shares Shorted/Prior | 5.47M/5.59M | Price | 0.03 |
| Gross Margin | 8.05% | Profit Margin | -104.30% | Avg. Volume | 15,602,648 | Target Price | 1.00 |
| Oper. Margin | -101.52% | Earnings Date | Oct 30 | Volume | 102,459,722 | Change | 0.00% |
ViewRay, Inc. designs, manufactures, and markets magnetic resonance imaging (MRI) guided radiation therapy systems to image and treat cancer patients in the United States, Italy, France, Taiwan, the United Kingdom, and internationally. It provides MRIdian, which is an MRI guided radiation therapy system that addresses beam distortion, skin toxicity, and other concerns. The company serves university research and teaching hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers through a network of direct sales force and distributors. ViewRay, Inc. was founded in 2004 and is headquartered in Denver, Colorado. On July 16, 2023, ViewRay, Inc., alongwith its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| EBRAHIMI FARHAD FRED | Director Director | Jul 17 | Sell | 0.06 | 8,203,610 | 492,217 | 07/21/23 | |
| JOHNSON B KRISTINE | Director Director | Jul 18 | Sell | 0.071 | 79,622 | 5,653 | 157,422 | 07/20/23 |
| Drake Scott William | Director Director | Jul 18 | Sell | 0.0622 | 2,408,747 | 149,824 | 1,591,615 | 07/20/23 |
| Dempsey James F. | Chief Scientific Off.. Chief Scientific Officer | Oct 24 | Sell | 4.13 | 42,000 | 173,460 | 654,368 | 03/21/23 |
| Dempsey James F. | Chief Scientific Off.. Chief Scientific Officer | Oct 24 | Option | 0.75 | 167,000 | 125,250 | 779,368 | 03/21/23 |
| SCHNABEL SUSAN C | Director Director | Nov 28 | Buy | 4.69 | 25,000 | 117,250 | 192,790 | 11/29/22 |
| SCHNABEL SUSAN C | Director Director | May 19 | Buy | 2.91 | 30,000 | 87,300 | 113,279 | 05/20/22 |
| JOHNSON B KRISTINE | Director Director | May 12 | Buy | 2.8176 | 40,000 | 112,704 | 40,000 | 05/13/22 |
| SCHNABEL SUSAN C | Director Director | May 10 | Buy | 2.65 | 10,000 | 26,500 | 83,279 | 05/12/22 |
| Castelein Caley | Director Director | May 10 | Buy | 2.55 | 1,415,000 | 3,608,250 | 1,545,600 | 05/12/22 |
| Prange Karen | Director Director | May 10 | Buy | 2.66 | 37,600 | 100,016 | 83,754 | 05/12/22 |
| Drake Scott William | President & CEO President & CEO | May 10 | Buy | 2.57 | 157,012 | 403,521 | 4,111,742 | 05/12/22 |
| Stassen Zachary William | Chief Financial Offi.. Chief Financial Officer | May 10 | Buy | 2.59 | 120,000 | 310,800 | 656,363 | 05/12/22 |
| Moore Daniel Jeffrey | Director Director | May 10 | Buy | 2.5945 | 96,358 | 250,001 | 272,998 | 05/12/22 |
| SCHNABEL SUSAN C | Director Director | May 09 | Buy | 2.41 | 10,000 | 24,100 | 73,279 | 05/11/22 |
| SCHNABEL SUSAN C | Director Director | Mar 10 | Buy | 3.83 | 25,000 | 95,750 | 35,335 | 03/14/22 |